Sinphar Pharmaceutical Co (TPE:1734) Other Current Payables: NT$360 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
81 GF Score
Price NT$32.35
GF Value NT$33.18
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Sinphar Pharmaceutical Co Other Current Payables?

Sinphar Pharmaceutical Co TPE:1734 +0.31% 81 Other Current Payables is NT$360 Mil as of Dec. 2025. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.18 (Fairly Valued). The stock has 1 warning sign investors should review.

Sinphar Pharmaceutical Co's Other Current Payables for the quarter that ended in Dec. 2025 was NT$360 Mil.

Sinphar Pharmaceutical Co's quarterly Other Current Payables declined from Jun. 2025 (NT$455 Mil) to Sep. 2025 (NT$303 Mil) but then increased from Sep. 2025 (NT$303 Mil) to Dec. 2025 (NT$360 Mil).

Sinphar Pharmaceutical Co's annual Other Current Payables increased from Dec. 2023 (NT$337 Mil) to Dec. 2024 (NT$337 Mil) and increased from Dec. 2024 (NT$337 Mil) to Dec. 2025 (NT$360 Mil).

Sinphar Pharmaceutical Co Other Current Payables Related Terms

Sinphar Pharmaceutical Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Other Current Payables Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 520.01 426.42 336.51 336.79 359.89

Sinphar Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 336.79 262.71 454.62 302.53 359.89
TPE:1734
81GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$360 Mil mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Other Current Payables of NT$360 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Sinphar Pharmaceutical Co and its competitors.
Is Sinphar Pharmaceutical Co's Other Current Payables too high?
Sinphar Pharmaceutical Co's current Other Current Payables is NT$360 Mil. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Other Current Payables compare to VRTX and REGN?
Sinphar Pharmaceutical Co's Other Current Payables of NT$360 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Other Current Payables is NT$360 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.18, compared to a current price of NT$32.35 — trading 2.5% below its estimated fair value. The current Other Current Payables is NT$360 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Other Current Payables is NT$360 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$32.35 is trading 2.5% below its estimated GF Value™ of NT$33.18. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Other Current Payables: NT$360 Mil
  • GF Value™: NT$33.18 vs. price of NT$32.35 (2.5% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score

Get the complete analysis for TPE:1734

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.35
Price
NT$33.18
GF Value